title: Intracavernous administration of bone marrow mononuclear cells: a new method of treating erectile dysfunction?
abstract: While PDE5 inhibitors have revolutionized treatment of ED, approximately 30% of patients are non-responsive. A significant cause of this is vascular and smooth muscle dysfunction, as well as nerve atrophy. Autologous administration of bone marrow mononuclear cells (BMMC) has been performed in over 2000 cardiac patients without adverse effects, for stimulation of angiogenesis/regeneration. Despite its ease of access, and dependence on effective vasculature for function, comparatively little has been perform in terms of BMMC therapy for ED. Here we outline the rationale for use of autologous BMMC in patients with ED, as well as provide early safety data on the first use of this procedure clinically.
authors.affiliation: Institute for Molecular Medicine, Huntington Beach, CA, USA. Thomas.ichim@gmail.com
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Ichim
authors.forename: Timothy
authors.initials: T
authors.lastname: Warbington
authors.forename: Octav
authors.initials: O
authors.lastname: Cristea
authors.forename: Joseph L
authors.initials: JL
authors.lastname: Chin
authors.forename: Amit N
authors.initials: AN
authors.lastname: Patel
mesh_terms: D000328:Adult; D001854:Bone Marrow Cells / Q000166:cytology*; D016026:Bone Marrow Transplantation / Q000379:methods*; D016207:Cytokines / Q000378:metabolism; D004730:Endothelium, Vascular / Q000473:pathology; D007172:Erectile Dysfunction / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000166:cytology*; D008297:Male; D018919:Neovascularization, Physiologic; D010413:Penis / Q000378:metabolism / Q000473:pathology; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use
chemical_list: D016207:Cytokines; D058986:Phosphodiesterase 5 Inhibitors